Showing results (121-130 of 277) with videos related to
Sort By:
Pageof 28
Cancer|October 5, 2017
First-in-human trial of the PI3Kβ-selective inhibitor SAR260301 in patients with advanced solid tumorsPhilippe L Bédard, Michael A Davies, Scott Kopetz, et al.Plos One|December 17, 2008
Early detection of erlotinib treatment response in NSCLC by 3'-deoxy-3'-[F]-fluoro-L-thymidine ([F]FLT) positron emission tomography (PET)Roland T Ullrich, Thomas Zander, Bernd Neumaier, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 12, 2022
Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast CancerFelipe Batalini, Niya Xiong, Nabihah Tayob, et al.Nature Communications|March 14, 2023
Polymerase θ inhibition activates the cGAS-STING pathway and cooperates with immune checkpoint blockade in models of BRCA-deficient cancerJeffrey Patterson-Fortin, Heta Jadhav, Constantia Pantelidou, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 25, 2024
A Translational Study of the ATR Inhibitor Berzosertib as Monotherapy in Four Molecularly Defined Cohorts of Advanced Solid TumorsGregory M Cote, Bose S Kochupurakkal, Khanh Do, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 6, 2021
Crizotinib in Patients With MET-Amplified NSCLCD Ross Camidge, Gregory A Otterson, Jeffrey W Clark, et al.Investigational New Drugs|September 4, 2015
A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumorsSuzanne F Jones, Lillian L Siu, Johanna C Bendell, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 29, 2022
Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II StudyVivek Subbiah, Irene Braña, Alessandra Longhi, et al.Oral Oncology|July 4, 2012
Phase II trial of the histone deacetylase inhibitor romidepsin in patients with recurrent/metastatic head and neck cancerMissak Haigentz, Mimi Kim, Catherine Sarta, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 7, 2014
DNA-PK-A candidate driver of hepatocarcinogenesis and tissue biomarker that predicts response to treatment and survivalLiam Cornell, Joanne M Munck, Clara Alsinet, et al.Pageof 28